Memory T Cell Responses Following Anti-CTLA-4 Antibody Treatment
Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.
Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.
Clinical Pearls:
- Because these treatments change the T cells that are circulating in patients, it may take time for patients to develop T cells that can see the cancer.
- Researchers found that patients who have high frequencies of T cells tend have the longest survival when receiving treatment with an anti-CTLA-4 antibody.
- By discovering the benefit of having this pre-existing response, physicians can make better choices when treating patients.
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
